COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,051 Articles (22,627 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 507: Articles 5061-5070  | Next

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
Dewald, F., Prikl, M., Ahmadov, E., Paluschinski, M., Kuehn, J., Elsner, C., Schulte, B., Schlotz, M., Oral, G., Knuefer, J., Bernhard, M., Michael, M., Luxenburger, M., Andree, M., Hennies, M. T., Hafezi, W., Mueller, M. M., Kuempers, P., Risse, J., Kill, C., Manegold, R. K., von Frantzki, U., Schulte, B., Richter, E., Monzon Posadas, W., Graeff, I., Kogej, M., Buening, A., Baum, M., Teipel, F., Mochtarzadeh, B., Wolff, M., Gruell, H., Di Cristanziano, V., Burst, V., Streeck, H., Dittmer, U., Ludwig, S., Timm, J., Klein, F.
10.1101/2022.12.31.22284088 — Posted: 2023-01-03
The illusion of personal health decisions for infectious disease management: disease spread in social contact networks
Michalska-Smith, M., Enns, E., White, L. A., Gilbertson, M. L., Craft, M. E.
10.1101/2023.01.01.22284075 — Posted: 2023-01-03
ACE2 Receptor Decoy is a Potent Prophylactic and Therapeutic for SARS-CoV-2
Tada, T., Dcosta, B. M., Zhou, H., Landau, N. R.
10.1101/2022.12.31.522401 — Posted: 2023-01-02
Lung lipid deposition in pneumonias of viral and non-viral aetiology
Potashnikova, D. M., Tvorogova, A. V., Saidova, A. A., Sotnikova, T. N., Arifulin, E. A., Lipina, T. V., Shirokova, O. M., Melnikov, E. S., Rodina, T. A., Valyaeva, A. A., Zharikova, A. A., Zayratyants, G. O., Zayratyants, O. V., Sheval, E. V., Margolis, L. B., Vasilieva, E. Y.
10.1101/2022.12.30.522299 — Posted: 2023-01-02
An engineered ACE2 decoy broadly neutralizes Omicron subvariants and shows therapeutic effect in SARS-CoV-2-infected cynomolgus macaques
Urano, E., Itoh, Y., Suzuki, T., Sasaki, T., Kishikawa, J.-i., Akamatsu, K., Higuchi, Y., Sakai, Y., Okamura, T., Mitoma, S., Sugihara, F., Takada, A., Kimura, M., Hirose, M., Sasaki, T., Koketsu, R., Tsuji, S., Yanagida, S., Shioda, T., Hara, E., Matoba, S., Matsuura, Y., Kanda, Y., Arase, H., Okada, M., Takagi, J., Kato, T., Hoshino, A., Yasutomi, Y., Saito, A., Okamoto, T.
10.1101/2022.12.29.522275 — Posted: 2023-01-02
Safety and Effectiveness of SA58 Nasal Spray against COVID-19 Infection in Medical Personnel：An Open-label, Blank-controlled Study
Si, S., Jin, C., Cao, Y. R., Li, J., Kan, B., Xue, F., Xie, X. S., Fang, L., Zeng, G., Zhang, S., Hu, Y., Dong, X.
10.1101/2022.12.27.22283698 — Posted: 2022-12-31
COVID-19 in Cambodia: Epidemiology, Response, and Lessons Learned, 27 January 2020 to 30 June 2022
Chhim, S., Ku, G. M., Mao, S., Put, W. v. d., Van Damme, W., Ir, P., Chhea, C., Or, V.
10.1101/2022.12.24.22283920 — Posted: 2022-12-31
On temporal changes in the role of different age groups in propagating the Omicron epidemic waves in England
Goldstein, E.
10.1101/2022.12.30.22283949 — Posted: 2022-12-31
A Statistical Analysis on COVID-19 Pandemic in the City of Toronto
Kaazempur-Mofrad, A.
10.1101/2022.12.28.22284001 — Posted: 2022-12-30
Effectiveness of Sotrovimab in Preventing COVID-19-related Hospitalizations or Deaths Among U.S. Veterans
Young-Xu, Y., Korves, C., Zwain, G., Satram, S., Drysdale, M., Reyes, C., Cheng, M. M., Epstein, L., Marconi, V. C., Ginde, A.
10.1101/2022.12.30.22284063 — Posted: 2022-12-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).